Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSIn healthy volunteers the GLP-1 drug liraglutide cut plasma vasopressin, and animal work traced the effect up to the brain and down to the kidney's aquaporin-2 water channel, with sex-dependent steps.
Dual GLP-1 and glucagon drugs protect the kidney, and a new mouse-and-human study says the glucagon half does it directly, by keeping a lysosomal proton pump clicked together inside tubule cells.
A Yale and Manchester study in female mice found that AgRP hunger neurons, long assumed to be switched off by GLP-1 drugs, are actually required for the drugs' full weight loss.
A 600,000-patient records study found that among people with type 2 diabetes on GLP-1 drugs, cannabis users had substantially higher death, heart, and kidney risk, dose-dependently. The honest read is a risk marker, not proof the drug fails or that cannabis is the cause.
A new mediation analysis of survodutide's phase 2 MASH trial splits the drug's liver benefit in two. The fat clearing tracked weight loss. The gains against inflammation and fibrosis mostly did not, pointing to the glucagon receptor working directly on the liver.
In a Melbourne study, 75 percent of people who had never met H5N1 already carried T cells that recognized it, because seasonal H1N1 and bird-flu hemagglutinin share a conserved stalk. The catch: the primed cells likely soften an infection rather than prevent one, and an H3N2-heavy immune history barely helps.
At least six reports since 2025 describe lithium climbing after patients on stable doses started a GLP-1 drug, and Europe has opened a safety signal. A new analysis says the acute spikes make sense, but a sustained per-dose rise does not.
A controlled rat study made surgically repaired Achilles tendons stronger and better organized with TB-500, saw no significant gain from BPC-157 on its own, and found the popular two-peptide stack beat neither peptide alone.
A pooled analysis of four randomized trials found tesamorelin reliably shrinks the deep abdominal fat that antiretroviral therapy can add, and raises lean mass. The endpoints are body measures, not health outcomes, and the discontinuation rate ran more than twice as high.
A 96,356-patient meta-analysis found every 90-day complication rate lower in GLP-1 users before hip and knee replacement, with hips carrying most of the benefit. The evidence is graded very low, and the all-favorable pattern is also the fingerprint of who gets the drug.
Neuropeptide Y stuck to graphene oxide and injected into the amygdala suppressed a conditioned fear response in rats, acting through specific receptor-bearing synapses rather than sedating the region. It is a delivery proof of concept in animals, with a strong framing on a freezing assay.
The first pooled analysis of GLP-1 exposure around conception found no change in the risk of high blood pressure in pregnancy (odds ratio 0.91). It rests on three US observational cohorts that disagreed with each other, so it rules out a large effect, not a small one.
In 31 obese patients, adding tirzepatide to standard biologic therapy improved symptoms, function, and skin over six months. Whether that is the drug treating the arthritis or just the weight coming off is the open question.
Novo Nordisk ran compounded and follow-on copies of semaglutide and liraglutide through immune-response assays and reported they carry different impurities. The chemistry is real. So is the conflict of interest.
Kisspeptin, the peptide that switches on puberty, throttled a RAS-driven cancer in the lab by cutting one downstream link (SP1 to N-cadherin) instead of drugging the mutated gene itself. It is a bench mechanism, not a treatment, but it hands the next lab a specific arrow to test.